Director share purchases

November 7, 2022

LungLife AI, Inc.
(the “Company” or “LungLife”)

Director share purchases

LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, announces that it has received notification of the following transactions in the Company’s common shares of US $0.0001 each (“Common Shares”) undertaken by directors.

On 2 November 2022, Paul Pagano, Chief Executive Officer, purchased 5,000 Common Shares at a price of 130 pence per share. Following this purchase, Paul Pagano now holds 5,000 Common Shares, representing approximately 0.02% of the outstanding share capital of the Company.

In addition, on 2 November 2022, David Anderson, Chief Financial Officer, purchased 5,000 Common Shares at a price of 130 pence per share. Following this purchase, David Anderson now holds 5,000 Common Shares, representing approximately 0.02% of the outstanding share capital of the Company.

For the full announcement, click HERE. 

Notification of transactions by Directors, Persons Discharging Managerial Responsibilities ("PDMRs") and persons closely associated with them.

1. Details of the person discharging managerial responsibilities / person closely associated
a) Name Paul Pagano
2. Reason for the Notification
a) Position/status Chief Executive Officer
b) Initial notification/amendment Initial notification
3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a) Name LungLife AI, Inc
b) LEI 549300VBVDIF0Y3OVI38
4. Details of the transaction(s):section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv)each place where transactions have been conducted
a) Description of the Financial instrument, type of instrument, identification code Common shares of $0.0001 each in the capital of the Company

ISIN: USU5500L1045

b) Nature of the Transaction Purchase of Common Shares
c) Price(s) and volume(s)
Price Volume
130 pence 5,000
d) Aggregated information

-     Aggregated volume

-     Price

As above
e) Date of the transaction 2/11/2022
f) Place of the transaction London Stock Exchange

 

Notification of transactions by Directors, Persons Discharging Managerial Responsibilities ("PDMRs") and persons closely associated with them.

1. Details of the person discharging managerial responsibilities / person closely associated
a) Name David Anderson
2. Reason for the Notification
a) Position/status Chief Financial Officer
b) Initial notification/amendment Initial notification
3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a) Name LungLife AI, Inc
b) LEI 549300VBVDIF0Y3OVI38
4. Details of the transaction(s):section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv)each place where transactions have been conducted
a) Description of the Financial instrument, type of instrument, identification code Common shares of $0.0001 each in the capital of the Company

ISIN: USU5500L1045

b) Nature of the Transaction Purchase of Common Shares
c) Price(s) and volume(s)
Price Volume
130 pence 5,000
d) Aggregated information

-     Aggregated volume

-     Price

As above
e) Date of the transaction 2/11/2022
f) Place of the transaction London Stock Exchange

 

 

Recent News

Final Pricing Determination
Total Voting Rights
Block Listing Six Monthly Return

Subscribe for Email Alerts

"*" indicates required fields

This field is for validation purposes and should be left unchanged.

© 2020 LungLIfe AI, Inc.
All rights reserved. LiquidBiopsy is a trademark of LungLife AI, Inc.
magnifiercrossmenuchevron-down